STAT+: Teva and Allergan reach $107 million deal with Rhode Island over opioid crisis

The deal calls for the companies to pay $28.5 million in cash. Teva will also provide doses of drugs used to treat overdoses and opioid use disorder.

Just as a trial was getting underway, Allergan and Teva Pharmaceutical reached a settlement worth $107 million with the state of Rhode Island over their alleged roles in fomenting the U.S. opioid crisis.

The deal calls for Teva to pay $21.5 million over 13 years and Allergan, a unit of AbbVie, to pay $8 million over six years. In addition, Teva will supply the state with two medicines to combat the crisis — valued at $78.5 million, based on wholesale prices — over the next decade. The medicines are Teva’s generic version of Narcan, a nasal spray used to reverse an opioid overdose, and buprenorphine, which combats opioid use disorder.

Continue to STAT+ to read the full story…